Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 54 articles: HTML format

Single Articles

July 2025
1. OU G, Gou J, Ou H, Zheng H, et al
   Gut markers for metastatic melanoma receiving immunotherapy.
   BMC Cancer. 2025;25:1083.
   PubMed     Abstract available
   
   
   May 2025
2. LUCKETT T, Ng CA, Lai-Kwon J, Kee D, et al
   Uncertainty and hope in people with metastatic uveal melanoma in the era of immunotherapy and targeted treatments: a theory-based qualitative study.
   BMC Cancer. 2025;25:939.
   PubMed     Abstract available
   
   
   
3. CHEN SH, Yu BY, Kuo WY, Lin YB, et al
   Unveiling the immune microenvironment of complex tissues and tumors in transcriptomics through a deconvolution approach.
   BMC Cancer. 2025;25.
   PubMed     Abstract available
   
   
   April 2025
4. YE M, Ren S, Luo H, Wu X, et al
   Integration of graph neural networks and transcriptomics analysis identify key pathways and gene signature for immunotherapy response and prognosis of skin melanoma.
   BMC Cancer. 2025;25:648.
   PubMed     Abstract available
   
   
   
5. ZHAO S, Li Z, Liu K, Wang G, et al
   Combining multi-omics analysis with machine learning to uncover novel molecular subtypes, prognostic markers, and insights into immunotherapy for melanoma.
   BMC Cancer. 2025;25:630.
   PubMed     Abstract available
   
   
   
6. ZHAO W, Chen Z, Fu W, Ye C, et al
   Induction of apoptosis and hypoxic stress in malignant melanoma cells via graphene-mediated far-infrared radiation.
   BMC Cancer. 2025;25:620.
   PubMed     Abstract available
   
   
   March 2025
7. MANGER I, Schmitt C, Berking C, French LE, et al
   Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study.
   BMC Cancer. 2025;25:565.
   PubMed     Abstract available
   
   
   
8. MOLONEY M, Harris PM, Kaczmarski P, Zheng S, et al
   Updated results of 3,050 non-melanoma skin cancer (NMSC) lesions in 1725 patients treated with high resolution dermal ultrasound-guided superficial radiotherapy, a multi-institutional study.
   BMC Cancer. 2025;25:526.
   PubMed     Abstract available
   
   
   January 2025
9. ZHOU L, Zhou Q, Guo Q, Lai P, et al
   Dual role of Cathepsin S in cutaneous melanoma: insights from mendelian randomization and bioinformatics analysis.
   BMC Cancer. 2025;25:104.
   PubMed     Abstract available
   
   
   
10. NASERI H, Safaei AA
    Diagnosis and prognosis of melanoma from dermoscopy images using machine learning and deep learning: a systematic literature review.
    BMC Cancer. 2025;25:75.
    PubMed     Abstract available
    
    
    
11. EVERATT R, Kuzmickiene I, Brasiuniene B, Vincerzevskiene I, et al
    Postdiagnostic use of antihypertensive medications and survival in colorectal, lung, corpus uteri, melanoma and kidney cancer patients with hypertension.
    BMC Cancer. 2025;25:38.
    PubMed     Abstract available
    
    
    December 2024
12. BORILOVA S, Grell P, Selingerova I, Gescheidtova L, et al
    Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer.
    BMC Cancer. 2024;24:1590.
    PubMed     Abstract available
    
    
    
13. FARIAS RM, Jiang Y, Levy EJ, Hwang C, et al
    Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy.
    BMC Cancer. 2024;24:1493.
    PubMed     Abstract available
    
    
    November 2024
14. ZHANG S, Zang L, Li Y, Pang Y, et al
    Numb and NumbL inhibit melanoma tumor growth by influencing the immune microenvironment.
    BMC Cancer. 2024;24:1419.
    PubMed     Abstract available
    
    
    
15. CAI X, Lin J, Li C, Xu T, et al
    MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study.
    BMC Cancer. 2024;24:1384.
    PubMed     Abstract available
    
    
    October 2024
16. FERRIER ST, Li M, Burnier JV
    Azacytidine treatment affects the methylation pattern of genomic and cell-free DNA in uveal melanoma cell lines.
    BMC Cancer. 2024;24:1299.
    PubMed     Abstract available
    
    
    
17. DI PIETRO FR, Marinelli D, Verkhovskaia S, Poti G, et al
    Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.
    BMC Cancer. 2024;24:1220.
    PubMed     Abstract available
    
    
    August 2024
18. YU H, Ding G, Gong Q, Ma J, et al
    Modulation of PD-L1 by Astragalus polysaccharide attenuates the induction of melanoma stem cell properties and overcomes immune evasion.
    BMC Cancer. 2024;24:1034.
    PubMed     Abstract available
    
    
    July 2024
19. GARCIA AM, Parra-Lara LG, Mendoza-Urbano DM, Bravo JC, et al
    Survival of patients with mucosal melanoma in Cali, Colombia: a retrospective cohort study.
    BMC Cancer. 2024;24:886.
    PubMed     Abstract available
    
    
    
20. YIN W, Li R, Zhang Z, Wang Y, et al
    Causal association between skin cancer and immune cells: mendelian randomization (MR) study.
    BMC Cancer. 2024;24:849.
    PubMed     Abstract available
    
    
    
21. TONDER JE, Bonnelykke-Behrndtz ML, Laurberg T, Rossell EL, et al
    Melanoma risk, tumour stage, and melanoma-specific mortality in individuals with diabetes: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:812.
    PubMed     Abstract available
    
    
    
22. DIDIER AJ, Nandwani SV, Watkins D, Fahoury AM, et al
    Patterns and trends in melanoma mortality in the United States, 1999-2020.
    BMC Cancer. 2024;24:790.
    PubMed     Abstract available
    
    
    June 2024
23. GAULT A, Hogarth L, Williams KC, Greystoke A, et al
    Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study.
    BMC Cancer. 2024;24:733.
    PubMed     Abstract available
    
    
    May 2024
24. KAMMINGA NCW, van der Veldt AAM, Wakkee M, van den Berge FR, et al
    From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.
    BMC Cancer. 2024;24:662.
    PubMed     Abstract available
    
    
    
25. CHRISTAKOUDI S, Tsilidis KK, Riboli E
    Prospective associations of leucocyte subtypes and obesity with the risk of developing cutaneous malignant melanoma in the UK Biobank cohort.
    BMC Cancer. 2024;24:625.
    PubMed     Abstract available
    
    
    
26. JANSSEN JC, van Dijk B, de Joode K, Aarts MJB, et al
    Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
    BMC Cancer. 2024;24:632.
    PubMed     Abstract available
    
    
    
27. MIAO L, Miao T, Zhang Y, Hao J, et al
    Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
    BMC Cancer. 2024;24:602.
    PubMed     Abstract available
    
    
    April 2024
28. ZHANG Y, Zheng J, Chen M, Zhao S, et al
    Modulating DNA damage response in uveal melanoma through embryonic stem cell microenvironment.
    BMC Cancer. 2024;24:519.
    PubMed     Abstract available
    
    
    
29. SHENG M, Sun R, Fu J, Lu G, et al
    The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
    BMC Cancer. 2024;24:399.
    PubMed     Abstract available
    
    
    March 2024
30. WHITMAN ED, Totev TI, Jiang S, da Costa WL Jr, et al
    Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.
    BMC Cancer. 2024;24:389.
    PubMed     Abstract available
    
    
    
31. NEVAKIVI R, Siiskonen H, Haimakainen S, Harvima IT, et al
    Spectrum of malignant and premalignant skin lesions in 505 adult subjects at risk of skin cancers.
    BMC Cancer. 2024;24:338.
    PubMed     Abstract available
    
    
    February 2024
32. ZHU Z, Wang W, Zha Y, Wang X, et al
    Development and validation of a nomogram for predicting overall survival in patients with sinonasal mucosal melanoma.
    BMC Cancer. 2024;24:184.
    PubMed     Abstract available
    
    
    January 2024
33. SAAMARTHY K, Ahlqvist K, Daams R, Balagunaseelan N, et al
    Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells.
    BMC Cancer. 2024;24:103.
    PubMed     Abstract available
    
    
    
34. WANG X, Li J, Li Y, Lv M, et al
    Single-cell analysis of the cellular landscape of vulvar melanoma provides new insight for immunotherapy administration.
    BMC Cancer. 2024;24:101.
    PubMed     Abstract available
    
    
    November 2023
35. TSAKMAKLIS A, Farowski F, Zenner R, Lesker TR, et al
    TIGIT(+) NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.
    BMC Cancer. 2023;23:1160.
    PubMed     Abstract available
    
    
    
36. ZHAO Y, Amorrortu RP, Stewart SC, Ghia KM, et al
    Melanoma and CLL co-occurrence and survival: role of KC history.
    BMC Cancer. 2023;23:1084.
    PubMed     Abstract available
    
    
    October 2023
37. LI L, Pei B, Feng Y
    Exogenous hormone therapy and non-melanoma skin cancer (keratinocyte carcinoma) risk in women: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:946.
    PubMed     Abstract available
    
    
    September 2023
38. JOSHY G, Khalatbari-Soltani S, Soga K, Butow P, et al
    Pain and its interference with daily living in relation to cancer: a comparative population-based study of 16,053 cancer survivors and 106,345 people without cancer.
    BMC Cancer. 2023;23:774.
    PubMed     Abstract available
    
    
    August 2023
39. LIU J, Luo B, Zhang P, Jiang K, et al
    Necroptosis-related LncRNAs in skin cutaneous melanoma: evaluating prognosis, predicting immunity, and guiding therapy.
    BMC Cancer. 2023;23:752.
    PubMed     Abstract available
    
    
    July 2023
40. OLATEJU OA, Zeng Z, Thornton JD, Mgbere O, et al
    Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors.
    BMC Cancer. 2023;23:655.
    PubMed     Abstract available
    
    
    June 2023
41. LIU W, Ji Y, Wang F, Li C, et al
    Morusin shows potent antitumor activity for melanoma through apoptosis induction and proliferation inhibition.
    BMC Cancer. 2023;23:602.
    PubMed     Abstract available
    
    
    
42. GEOFFROIS L, Harle A, Sahki N, Sikanja A, et al
    Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.
    BMC Cancer. 2023;23:554.
    PubMed     Abstract available
    
    
    
43. LI H, Sun X, Zhao Y, Zhang C, et al
    Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction.
    BMC Cancer. 2023;23:528.
    PubMed     Abstract available
    
    
    May 2023
44. DIETSCH B, Weller C, Sticht C, de la Torre C, et al
    Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern.
    BMC Cancer. 2023;23:436.
    PubMed     Abstract available
    
    
    
45. WU N, Sun H, Sun Q, Zhang F, et al
    Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:414.
    PubMed     Abstract available
    
    
    
46. GRAVIS G, Marino P, Olive D, Penault-LLorca F, et al
    A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
    BMC Cancer. 2023;23:393.
    PubMed     Abstract available
    
    
    
47. LIU J, Pei S, Zhang P, Jiang K, et al
    Liquid-liquid phase separation throws novel insights into treatment strategies for skin cutaneous melanoma.
    BMC Cancer. 2023;23:388.
    PubMed     Abstract available
    
    
    April 2023
48. TANG W, Shao Q, He Z, Zhang X, et al
    Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer Analysis.
    BMC Cancer. 2023;23:303.
    PubMed     Abstract available
    
    
    
49. REZAIE Y, Fattahi F, Mashinchi B, Kamyab Hesari K, et al
    High expression of Talin-1 is associated with tumor progression and recurrence in melanoma skin cancer patients.
    BMC Cancer. 2023;23:302.
    PubMed     Abstract available
    
    
    March 2023
50. SUN S, Deng M, Wen J, Chen X, et al
    Aspartate beta-hydroxylase domain containing 1 as a prognostic marker associated with immune infiltration in skin cutaneous melanoma.
    BMC Cancer. 2023;23:292.
    PubMed     Abstract available
    
    
    
51. KAMMINGA NCW, Wakkee M, De Bruin RJ, van der Veldt AAM, et al
    Oncological healthcare providers' perspectives on appropriate melanoma survivorship care: a qualitative focus group study.
    BMC Cancer. 2023;23:278.
    PubMed     Abstract available
    
    
    
52. HERRSPIEGEL C, Plastino F, Lardner E, Seregard S, et al
    A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival.
    BMC Cancer. 2023;23:277.
    PubMed     Abstract available
    
    
    
53. JOHNSON DB, Atkins MB, Hennessy C, Wise-Draper T, et al
    Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.
    BMC Cancer. 2023;23:265.
    PubMed     Abstract available
    
    
    
54. SHEN Y, Li M, Liao L, Gao S, et al
    Plasma exosome-derived connexin43 as a promising biomarker for melanoma patients.
    BMC Cancer. 2023;23:242.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.